Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will have its CEO, Ryan Spencer, present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 p.m. E.T. The presentation will be accessible via webcast through the company's website's 'Events & Presentations' section.

Dynavax specializes in developing novel vaccines, with its first product HEPLISAV-B® approved in the U.S. and EU for hepatitis B prevention in adults. The company is also advancing research on vaccine adjuvants, including collaborations for COVID-19 vaccines.

EMERYVILLE, Calif., June 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m. E.T.

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-301309437.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax present at the Goldman Sachs Healthcare Conference?

Dynavax will present on June 10, 2021, at 3:50 p.m. E.T.

Who is presenting for Dynavax at the conference?

CEO Ryan Spencer will be the presenter for Dynavax.

How can I access Dynavax's presentation?

The presentation can be accessed via webcast on Dynavax's 'Events & Presentations' page on their website.

What is Dynavax known for?

Dynavax is known for developing novel vaccines and its product HEPLISAV-B® for hepatitis B prevention.

What collaborations is Dynavax involved in?

Dynavax is collaborating on adjuvanted vaccines for COVID-19, pertussis, and universal influenza.